Novasep to supply ingredient for Tetraphase's candidate superbug buster eravacycline

By Gareth Macdonald

- Last updated on GMT


Related tags U.s. securities and exchange commission Pharmaceutical drug Pharmacology

Tetraphase Pharmaceutical Inc. has hired Novasep to make commercial supplies of the active ingredient for its candidate antibiotic eravacycline.

The deal will see Novasep produce eravacycline at its manufacturing facility in Chasse sur Rhône, France.

The contract manufacturer has been making the active pharmaceutical ingredient (API) for clinical trials for Tetraphase since 2014.

In July​, Tetraphase hired contractor Patheon NV to formulate and package eravacycline.

According to a US Securities and Exchange Commission (SEC), filing production will take place at Patheon’s facility in the UK.

At the time, Tetraphase said it expected to sign two further agreements with Patheon covering production at sites in Greenville North Carolina and Ferentino, Italy.

A representative for Tetraphase told us Novasep will work alongside Patheon, explaining, “Novasep supplies the API, and Patheon supplies the drug product​.”

Phase III candidate

Tetraphase designed eravacycline to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

The US Food and Drug Administration (FDA) has assigned the drug Qualified Infectious Disease Product​ (QIDP) and Fast Track status.

Tetraphase is testing the drug in patients with complicated urinary tract Infections in a Phase III​ trial at sites in the US and Europe.

Tetraphase developed eravacycline developed using synthesis methods settled by researchers at Harvard University in 2005​.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us